| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatoblastoma | 19 | 2024 | 180 | 8.150 |
Why?
|
| Liver Neoplasms | 29 | 2024 | 1316 | 5.860 |
Why?
|
| Neuroblastoma | 24 | 2021 | 529 | 2.570 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2024 | 933 | 1.620 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 6 | 2024 | 94 | 1.300 |
Why?
|
| Sarcoma | 6 | 2024 | 184 | 1.150 |
Why?
|
| Pancreatic Neoplasms | 4 | 2022 | 690 | 1.120 |
Why?
|
| Margins of Excision | 2 | 2024 | 51 | 1.100 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2024 | 74 | 0.970 |
Why?
|
| Sarcoma, Synovial | 1 | 2024 | 21 | 0.910 |
Why?
|
| Child | 57 | 2025 | 24617 | 0.890 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2022 | 91 | 0.860 |
Why?
|
| Neuroendocrine Tumors | 3 | 2021 | 54 | 0.860 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2024 | 1157 | 0.820 |
Why?
|
| Infant | 32 | 2025 | 12604 | 0.770 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 41 | 0.750 |
Why?
|
| Prognosis | 18 | 2024 | 4686 | 0.740 |
Why?
|
| Humans | 103 | 2025 | 125362 | 0.740 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 10 | 0.740 |
Why?
|
| Hepatectomy | 4 | 2023 | 112 | 0.720 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 21 | 0.720 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 43 | 0.710 |
Why?
|
| Peritonitis | 1 | 2021 | 78 | 0.710 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 42 | 0.700 |
Why?
|
| Metastasectomy | 2 | 2020 | 10 | 0.670 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2020 | 35 | 0.670 |
Why?
|
| Adolescent | 37 | 2025 | 19430 | 0.660 |
Why?
|
| Child, Preschool | 33 | 2025 | 14151 | 0.660 |
Why?
|
| Retrospective Studies | 35 | 2024 | 16369 | 0.650 |
Why?
|
| Cell Line, Tumor | 22 | 2024 | 3420 | 0.650 |
Why?
|
| Doxorubicin | 11 | 2024 | 288 | 0.640 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 1654 | 0.620 |
Why?
|
| Pneumonectomy | 2 | 2021 | 144 | 0.610 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2021 | 746 | 0.570 |
Why?
|
| Liver Transplantation | 3 | 2023 | 1042 | 0.560 |
Why?
|
| Databases, Factual | 8 | 2019 | 1172 | 0.540 |
Why?
|
| Up-Regulation | 2 | 2021 | 875 | 0.530 |
Why?
|
| Indocyanine Green | 3 | 2024 | 57 | 0.530 |
Why?
|
| Treatment Outcome | 18 | 2023 | 12287 | 0.520 |
Why?
|
| Female | 61 | 2025 | 66821 | 0.520 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 376 | 0.490 |
Why?
|
| Postoperative Complications | 7 | 2021 | 3056 | 0.490 |
Why?
|
| Dipeptides | 2 | 2016 | 57 | 0.490 |
Why?
|
| Liver | 3 | 2024 | 1749 | 0.490 |
Why?
|
| Adenoma, Liver Cell | 1 | 2015 | 4 | 0.480 |
Why?
|
| Hernia, Abdominal | 1 | 2015 | 19 | 0.470 |
Why?
|
| Kidney Neoplasms | 4 | 2025 | 440 | 0.470 |
Why?
|
| Cell Proliferation | 12 | 2019 | 2373 | 0.470 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 34 | 0.470 |
Why?
|
| Male | 51 | 2025 | 61566 | 0.460 |
Why?
|
| Wilms Tumor | 3 | 2025 | 117 | 0.460 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2014 | 6 | 0.460 |
Why?
|
| Intestinal Volvulus | 1 | 2015 | 38 | 0.460 |
Why?
|
| N-Myc Proto-Oncogene Protein | 4 | 2021 | 64 | 0.440 |
Why?
|
| Survival Rate | 12 | 2025 | 2050 | 0.420 |
Why?
|
| Follow-Up Studies | 14 | 2024 | 5171 | 0.420 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2024 | 914 | 0.420 |
Why?
|
| Chronic Pain | 1 | 2015 | 121 | 0.410 |
Why?
|
| Apoptosis | 12 | 2021 | 1818 | 0.400 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 681 | 0.400 |
Why?
|
| Abdominal Pain | 1 | 2015 | 306 | 0.400 |
Why?
|
| Combined Modality Therapy | 8 | 2024 | 1240 | 0.400 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 280 | 0.390 |
Why?
|
| Analgesia, Epidural | 2 | 2022 | 29 | 0.370 |
Why?
|
| Electricity | 1 | 2011 | 9 | 0.370 |
Why?
|
| Hemangioma | 2 | 2018 | 94 | 0.370 |
Why?
|
| Crystallization | 1 | 2011 | 83 | 0.360 |
Why?
|
| Neoplasm Staging | 10 | 2022 | 1275 | 0.360 |
Why?
|
| Alanine | 1 | 2011 | 187 | 0.350 |
Why?
|
| Lasers | 1 | 2011 | 114 | 0.350 |
Why?
|
| Infant, Newborn | 18 | 2025 | 8273 | 0.350 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2019 | 122 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 1982 | 0.340 |
Why?
|
| Thoracic Neoplasms | 3 | 2021 | 37 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 544 | 0.320 |
Why?
|
| Mice | 19 | 2024 | 17750 | 0.320 |
Why?
|
| Survival Analysis | 9 | 2021 | 1495 | 0.320 |
Why?
|
| Pancreatectomy | 3 | 2022 | 137 | 0.310 |
Why?
|
| Optical Imaging | 2 | 2021 | 66 | 0.310 |
Why?
|
| Osteosarcoma | 3 | 2021 | 255 | 0.300 |
Why?
|
| Surgical Oncology | 3 | 2024 | 12 | 0.300 |
Why?
|
| Healthcare Disparities | 3 | 2017 | 439 | 0.300 |
Why?
|
| Animals | 24 | 2024 | 34319 | 0.280 |
Why?
|
| Cell Survival | 6 | 2021 | 821 | 0.280 |
Why?
|
| Reoperation | 2 | 2024 | 830 | 0.270 |
Why?
|
| Biopsy | 3 | 2018 | 1244 | 0.270 |
Why?
|
| Mice, Nude | 9 | 2021 | 725 | 0.270 |
Why?
|
| Quinazolines | 2 | 2019 | 175 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 3 | 2015 | 15 | 0.270 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 78 | 0.270 |
Why?
|
| Dual-Specificity Phosphatases | 3 | 2015 | 22 | 0.270 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 126 | 0.260 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2019 | 62 | 0.260 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2006 | 42 | 0.250 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 30 | 0.250 |
Why?
|
| Carcinoma | 4 | 2016 | 290 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2022 | 366 | 0.240 |
Why?
|
| Thyroidectomy | 2 | 2017 | 100 | 0.240 |
Why?
|
| Vincristine | 2 | 2024 | 191 | 0.240 |
Why?
|
| Quinolines | 2 | 2017 | 103 | 0.240 |
Why?
|
| Gene Knockdown Techniques | 4 | 2021 | 367 | 0.240 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2017 | 436 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 79 | 0.240 |
Why?
|
| Bone Neoplasms | 2 | 2020 | 427 | 0.230 |
Why?
|
| Rhabdomyosarcoma | 2 | 2017 | 191 | 0.230 |
Why?
|
| Membrane Proteins | 2 | 2009 | 1538 | 0.230 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2019 | 145 | 0.230 |
Why?
|
| Etoposide | 4 | 2019 | 115 | 0.220 |
Why?
|
| Adult | 17 | 2024 | 29543 | 0.220 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 56 | 0.220 |
Why?
|
| Thoracoscopy | 2 | 2021 | 43 | 0.220 |
Why?
|
| Thyroid Neoplasms | 2 | 2017 | 189 | 0.210 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 420 | 0.210 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 77 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1244 | 0.210 |
Why?
|
| Disease-Free Survival | 7 | 2020 | 880 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3605 | 0.200 |
Why?
|
| Dependovirus | 1 | 2024 | 128 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 625 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 1025 | 0.190 |
Why?
|
| Esophageal Stenosis | 1 | 2002 | 46 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 58 | 0.190 |
Why?
|
| Heart Defects, Congenital | 3 | 2024 | 1832 | 0.190 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 19 | 0.190 |
Why?
|
| Recurrence | 2 | 2023 | 1394 | 0.190 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 587 | 0.190 |
Why?
|
| Young Adult | 13 | 2025 | 9061 | 0.190 |
Why?
|
| Chromatin Assembly Factor-1 | 1 | 2021 | 9 | 0.190 |
Why?
|
| Hep G2 Cells | 2 | 2018 | 86 | 0.190 |
Why?
|
| Ganglioneuroblastoma | 1 | 2021 | 6 | 0.190 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 1714 | 0.190 |
Why?
|
| Ganglioneuroma | 1 | 2021 | 17 | 0.190 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2021 | 18 | 0.190 |
Why?
|
| Cyanosis | 1 | 2001 | 42 | 0.180 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 1362 | 0.180 |
Why?
|
| Pancreas | 1 | 2022 | 220 | 0.180 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.180 |
Why?
|
| Monitoring, Intraoperative | 1 | 2001 | 133 | 0.180 |
Why?
|
| Heterografts | 5 | 2024 | 175 | 0.170 |
Why?
|
| Carbon Dioxide | 1 | 2001 | 279 | 0.170 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 384 | 0.170 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 62 | 0.160 |
Why?
|
| Drug Synergism | 5 | 2019 | 227 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2017 | 80 | 0.160 |
Why?
|
| Nephrectomy | 2 | 2018 | 178 | 0.160 |
Why?
|
| Thoracotomy | 1 | 2020 | 110 | 0.160 |
Why?
|
| Piperidones | 1 | 2019 | 7 | 0.160 |
Why?
|
| Thoracic Wall | 2 | 2019 | 39 | 0.160 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 216 | 0.160 |
Why?
|
| Signal Transduction | 9 | 2021 | 4595 | 0.160 |
Why?
|
| Piperazines | 1 | 2021 | 242 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 49 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 733 | 0.150 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2019 | 51 | 0.150 |
Why?
|
| Risk Assessment | 6 | 2020 | 3431 | 0.150 |
Why?
|
| Cyclin D1 | 1 | 2018 | 113 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2021 | 340 | 0.150 |
Why?
|
| Gene Dosage | 1 | 2020 | 445 | 0.150 |
Why?
|
| Dysgerminoma | 1 | 2017 | 5 | 0.150 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 59 | 0.140 |
Why?
|
| Age Factors | 6 | 2019 | 2818 | 0.140 |
Why?
|
| Ascites | 1 | 2018 | 93 | 0.140 |
Why?
|
| Consensus | 1 | 2021 | 644 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 2 | 2016 | 184 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 559 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 314 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 210 | 0.140 |
Why?
|
| United States | 11 | 2025 | 10909 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4409 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 1902 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2017 | 12 | 0.140 |
Why?
|
| Fertility Preservation | 1 | 2017 | 53 | 0.140 |
Why?
|
| Aniline Compounds | 1 | 2017 | 19 | 0.130 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2016 | 36 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 134 | 0.130 |
Why?
|
| Carcinoma, Lobular | 1 | 2017 | 24 | 0.130 |
Why?
|
| Sacroiliac Joint | 1 | 2016 | 5 | 0.130 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1534 | 0.130 |
Why?
|
| Neurofibrosarcoma | 1 | 2016 | 5 | 0.130 |
Why?
|
| Sacrum | 1 | 2016 | 30 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2016 | 30 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 664 | 0.130 |
Why?
|
| Spinal Nerve Roots | 1 | 2016 | 26 | 0.130 |
Why?
|
| Pelvic Bones | 1 | 2016 | 27 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 1065 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 35 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2096 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 239 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 134 | 0.130 |
Why?
|
| Aminopyridines | 1 | 2016 | 57 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2015 | 939 | 0.130 |
Why?
|
| src-Family Kinases | 1 | 2017 | 91 | 0.130 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 123 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 85 | 0.130 |
Why?
|
| Nitriles | 1 | 2017 | 146 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2017 | 120 | 0.130 |
Why?
|
| Gene Amplification | 2 | 2014 | 236 | 0.130 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2015 | 11 | 0.130 |
Why?
|
| Laparoscopy | 1 | 2001 | 491 | 0.130 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 57 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 37 | 0.120 |
Why?
|
| Tumor Burden | 4 | 2019 | 231 | 0.120 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2016 | 101 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 34 | 0.120 |
Why?
|
| Benzoxazoles | 1 | 2015 | 11 | 0.120 |
Why?
|
| Carcinoid Tumor | 1 | 2015 | 26 | 0.120 |
Why?
|
| Appendiceal Neoplasms | 1 | 2015 | 18 | 0.120 |
Why?
|
| Parathyroid Neoplasms | 1 | 2014 | 22 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2015 | 105 | 0.120 |
Why?
|
| Necrosis | 1 | 2015 | 209 | 0.110 |
Why?
|
| Parathyroidectomy | 1 | 2014 | 49 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 240 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Zearalenone | 1 | 2013 | 4 | 0.110 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2014 | 38 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1909 | 0.110 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 88 | 0.110 |
Why?
|
| Gastrostomy | 1 | 2014 | 87 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 472 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 45 | 0.110 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 210 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 126 | 0.110 |
Why?
|
| Lipoblastoma | 1 | 2013 | 6 | 0.110 |
Why?
|
| Health Resources | 1 | 2014 | 116 | 0.100 |
Why?
|
| Adenoma | 1 | 2014 | 128 | 0.100 |
Why?
|
| alpha-Fetoproteins | 1 | 2014 | 132 | 0.100 |
Why?
|
| Thiophenes | 1 | 2013 | 69 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 2520 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 96 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 168 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 248 | 0.100 |
Why?
|
| Base Sequence | 2 | 2009 | 3111 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 547 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 130 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 706 | 0.100 |
Why?
|
| Intestinal Perforation | 1 | 2013 | 56 | 0.100 |
Why?
|
| Cohort Studies | 6 | 2021 | 4828 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2014 | 1639 | 0.100 |
Why?
|
| Abdominal Neoplasms | 1 | 2012 | 33 | 0.100 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 3900 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 503 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2015 | 377 | 0.090 |
Why?
|
| Thermogravimetry | 1 | 2011 | 5 | 0.090 |
Why?
|
| Transfection | 2 | 2014 | 1076 | 0.090 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2011 | 30 | 0.090 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2011 | 45 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 144 | 0.090 |
Why?
|
| Vibration | 1 | 2011 | 32 | 0.090 |
Why?
|
| Fundoplication | 2 | 2002 | 69 | 0.090 |
Why?
|
| Neurons | 1 | 2021 | 1944 | 0.090 |
Why?
|
| Salivation | 1 | 2011 | 6 | 0.090 |
Why?
|
| X-Ray Diffraction | 1 | 2011 | 96 | 0.090 |
Why?
|
| Esophagoplasty | 1 | 2011 | 12 | 0.090 |
Why?
|
| Glycopyrrolate | 1 | 2011 | 9 | 0.090 |
Why?
|
| Chest Tubes | 1 | 2011 | 35 | 0.090 |
Why?
|
| Mutation | 3 | 2022 | 5905 | 0.090 |
Why?
|
| Intestines | 1 | 2015 | 577 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 334 | 0.090 |
Why?
|
| Operative Time | 2 | 2021 | 165 | 0.090 |
Why?
|
| Anastomotic Leak | 1 | 2011 | 31 | 0.090 |
Why?
|
| Muscarinic Antagonists | 1 | 2011 | 37 | 0.090 |
Why?
|
| Incidence | 4 | 2025 | 3134 | 0.090 |
Why?
|
| Esophageal Atresia | 1 | 2011 | 51 | 0.090 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2011 | 48 | 0.090 |
Why?
|
| Analgesics | 2 | 2022 | 127 | 0.090 |
Why?
|
| Age Distribution | 3 | 2016 | 418 | 0.080 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 358 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 295 | 0.080 |
Why?
|
| SEER Program | 2 | 2025 | 202 | 0.080 |
Why?
|
| Melanoma | 1 | 2017 | 943 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 860 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 92 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 108 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 2182 | 0.080 |
Why?
|
| Computational Biology | 2 | 2014 | 819 | 0.080 |
Why?
|
| Pain, Postoperative | 2 | 2022 | 259 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2014 | 648 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1692 | 0.070 |
Why?
|
| Infant, Premature | 2 | 2019 | 833 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2006 | 2909 | 0.070 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 407 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2019 | 128 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2007 | 121 | 0.060 |
Why?
|
| Esophagus | 2 | 2011 | 223 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2020 | 228 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 2799 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 1315 | 0.060 |
Why?
|
| Texas | 3 | 2023 | 3581 | 0.060 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2017 | 166 | 0.060 |
Why?
|
| Sirolimus | 2 | 2017 | 227 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2022 | 620 | 0.060 |
Why?
|
| COS Cells | 1 | 2005 | 275 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2005 | 295 | 0.060 |
Why?
|
| Catalytic Domain | 1 | 2005 | 162 | 0.060 |
Why?
|
| Liquid Biopsy | 1 | 2024 | 14 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 143 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2019 | 739 | 0.060 |
Why?
|
| Ifosfamide | 1 | 2024 | 31 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2009 | 2813 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 859 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 657 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 658 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2024 | 78 | 0.060 |
Why?
|
| Registries | 2 | 2025 | 1434 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 114 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 898 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2009 | 3044 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 2057 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2024 | 210 | 0.050 |
Why?
|
| Aged | 5 | 2019 | 19722 | 0.050 |
Why?
|
| Morphine | 1 | 2022 | 83 | 0.050 |
Why?
|
| Dilatation | 1 | 2002 | 66 | 0.050 |
Why?
|
| Myofibroma | 1 | 2021 | 9 | 0.050 |
Why?
|
| Bays | 1 | 2021 | 6 | 0.050 |
Why?
|
| Length of Stay | 2 | 2021 | 1310 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 344 | 0.050 |
Why?
|
| Pulmonary Blastoma | 1 | 2021 | 11 | 0.050 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2001 | 5 | 0.050 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2001 | 30 | 0.050 |
Why?
|
| Tidal Volume | 1 | 2001 | 39 | 0.050 |
Why?
|
| ARNTL Transcription Factors | 1 | 2021 | 39 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1427 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2021 | 56 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 110 | 0.040 |
Why?
|
| Probability | 1 | 2001 | 318 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 19 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2718 | 0.040 |
Why?
|
| Middle Aged | 5 | 2019 | 26763 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 6141 | 0.040 |
Why?
|
| Endosonography | 1 | 2020 | 78 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 38 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2019 | 66 | 0.040 |
Why?
|
| Foot Diseases | 1 | 2019 | 23 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 688 | 0.040 |
Why?
|
| Adenoma, Islet Cell | 1 | 2019 | 8 | 0.040 |
Why?
|
| Protein Unfolding | 1 | 2019 | 10 | 0.040 |
Why?
|
| Thigh | 1 | 2019 | 51 | 0.040 |
Why?
|
| Zebrafish | 1 | 2021 | 380 | 0.040 |
Why?
|
| Extremities | 1 | 2019 | 83 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 292 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 1284 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 101 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1633 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1756 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2020 | 238 | 0.040 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2019 | 201 | 0.040 |
Why?
|
| Pediatrics | 2 | 2017 | 1158 | 0.040 |
Why?
|
| para-Aminobenzoates | 1 | 2017 | 5 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 1339 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2017 | 36 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 215 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 412 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 299 | 0.030 |
Why?
|
| Chickens | 1 | 2017 | 636 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 25 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 245 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 73 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2017 | 145 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 29 | 0.030 |
Why?
|
| Social Class | 1 | 2017 | 190 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 567 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 50 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 586 | 0.030 |
Why?
|
| Kidney | 2 | 2015 | 1363 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 778 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 174 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 7 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 165 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2017 | 284 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 133 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 63 | 0.030 |
Why?
|
| Appendix | 1 | 2015 | 15 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6558 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 29 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 6311 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 168 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 473 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 71 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 196 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 586 | 0.030 |
Why?
|
| Neural Prostheses | 1 | 2014 | 4 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 23 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 206 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 70 | 0.030 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Sciatic Nerve | 1 | 2014 | 55 | 0.030 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2013 | 18 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 280 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 235 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 305 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2014 | 118 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 129 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2414 | 0.030 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2013 | 8 | 0.030 |
Why?
|
| Nerve Regeneration | 1 | 2014 | 75 | 0.030 |
Why?
|
| Liposarcoma | 1 | 2013 | 22 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 670 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 1275 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 530 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2014 | 626 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 561 | 0.020 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 130 | 0.020 |
Why?
|
| Genes, myc | 1 | 2012 | 105 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 772 | 0.020 |
Why?
|
| Thoracostomy | 1 | 2011 | 26 | 0.020 |
Why?
|
| Colostomy | 1 | 2011 | 26 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 682 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2013 | 353 | 0.020 |
Why?
|
| Anal Canal | 1 | 2011 | 82 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1017 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 521 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 732 | 0.020 |
Why?
|
| Spine | 1 | 2011 | 142 | 0.020 |
Why?
|
| Limb Deformities, Congenital | 1 | 2011 | 105 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 759 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2009 | 32 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 175 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2014 | 887 | 0.020 |
Why?
|
| Trachea | 1 | 2011 | 203 | 0.020 |
Why?
|
| Benzazepines | 1 | 2009 | 64 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 910 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1802 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2011 | 301 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 809 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 766 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2880 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3729 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2013 | 1016 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 10298 | 0.010 |
Why?
|